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Rho-associated  coiled-coil  forming  protein  kinases  (ROCKs),  the  downstream  target  proteins  of  RhoA,
are ubiquitously  expressed  serine-threonine  protein  kinases.  ROCKs  have  diverse  cellular  functions,  e.g.
smooth muscle  contraction,  actin  cytoskeleton  organization,  cell  adhesion,  and  gene  expression.  Accu-
mulating  evidence  has  revealed  that  ROCKs  are  substantially  involved  in  cardiovascular  disorders  such  as
angina,  cerebral  ischemia,  myocardial  ischemia,  and  cardiac  hypertrophy.  So  far,  the  signiﬁcant  relation-
ship  of ROCKs  with  endothelial  function  has  been  reported.  ROCKs  inhibition  by statins  or  other  selective
inhibitors  leads  to the  upregulation  and  activation  of endothelial  nitric  oxide  synthase,  resulting  in  the
reduction  of vascular  inﬂammation  and  atherosclerosis.  Meanwhile,  it has  been  also  demonstrated  that
endogenous  nitric oxide  could  inhibit  RhoA/ROCK  signaling  pathway.  Taken  together,  there  might  be  crit-ndothelial function
therosclerosis
ical crosstalk  of ROCKs  with  endothelial  function.  In  addition,  we further  focus  on  leukocyte  ROCK  activity
as a surrogate  marker  in patients  with  atherosclerosis-related  diseases.  Indeed,  leukocyte  ROCK  activity
has been  shown  to be increased  in  atherosclerotic  patients,  indicating  the  possible  usage of  leukocyte
ROCK  activity  as a  surrogate  marker  similar  to endothelial  function  evaluated  by ﬂow-mediated  dilation.
Here,  we  review  concerning  ROCK  signaling  pathway,  especially  focusing  on  the  crosstalk  of  ROCKs  with
endothelial  function.©  2012  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
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ho-associated coiled-coil-forming protein kinases (ROCKs) with changes in the actin cytoskeleton, such as cell adhesion,
motility, migration, and contraction [2].  Downstream targets ofSmall GTP-binding proteins act as molecular “on–off” switches
o control multiple signaling pathways [1].  Among the Ras, Rho,
ab, and Ran subfamilies, Rho GTPases are especially associated
∗ Corresponding authors at: 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551,
apan. Tel.: +81 82 257 5818; fax: +81 82 256 7104.
E-mail addresses: knoma@hiroshima-u.ac.jp (K. Noma),
higashi@hiroshima-u.ac.jp (Y. Higashi).
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.03.005Rho GTPases, such as citron kinase, p140mDia, protein kinase N
(PKN), p21-activated protein kinase (PAK), rhophillin, and rhotekin,
are involved in actin cytoskeletal reorganization. Rho-associated
coiled-coil forming protein kinases (ROCKs) are just one of the
downstream targets of RhoA and regulate downstream target pro-
teins of ROCK such as myosin light chain phosphatase (MLCPh). For
instance, ROCKs increase myosin light chain (MLC) phosphoryla-
tion through phosphorylating the myosin binding subunit (MBS)
on MLCP and inhibiting the activity of MLCP, leading to vascular
vier Ltd. All rights reserved.
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mooth muscle cell (VSMC) contraction [3]. Therefore, the primary
ole of ROCKs is to enhance actin–myosin association.
Accumulating evidence has revealed the signiﬁcant relationship
f ROCKs with cardiovascular related disorders including in vitro,
n vivo, and human studies [4].  Indeed, ROCKs are shown to be
ctivated in patients with cardiovascular risk factors and diseases,
uggesting that ROCKs inhibition may  be a novel therapeutic target
n the cardiovascular system [5,6].
OCK isoform
ROCKs consist of two isoforms, namely ROCK1 and ROCK2.
OCK1, known as ROK/Rho-kinase /p160ROCK, is located on
hromosome 18, and encodes a 1354 amino acid protein. ROCK2,
lso known as ROK/Rho-kinase , is located on chromosome 12
nd contains 1388 amino acids [7].
ROCK1 and ROCK2 share an overall 64% homology in amino-acid
equence and 83% homology in their kinase domains. Also, ROCK1
nd ROCK2 share 45–50% homology to other actin cytoskeletal
inases such as citron kinase, myotonic dystrophy kinase (DMPK),
nd myotonic dystrophy-related cdc42-binding kinase (MRCK) [7].
OCKs consist of an amino-terminal kinase domain, followed by
 mid  coiled-coil-forming lesion containing a Rho-binding domain
RBD), and carboxyl-terminal cysteine-rich domain (CRD) located
ithin the pleckstrin homology (PH) motif. ROCK1 and ROCK2
re ubiquitously expressed in mouse tissues from early embry-
nic development to adulthood. ROCK1 mRNA is preferentially
xpressed in lung, liver, spleen, kidney, and testis, while ROCK2
RNA is highly expressed in the heart and brain [8–10]. In addition,
mmuno-localization and cell-fractionation studies have shown
hat ROCK2 is distributed mainly in the cytoplasm [3].  Activated
TP-bound RhoA translocates ROCK2 from cytoplasm to mem-
ranes. Indeed, a small amount of ROCK2 has been found in the
embrane fraction, and some immunostaining is detectable at the
ell periphery or membranes of growing cells [3].  On the other hand,
ittle is known concerning the intracellular localization of ROCK1.
 study suggests that ROCK1 may  be co-localized to centrosomes
11].
Previously, ROCK1-deﬁcient (ROCK1−/−) and ROCK2-deﬁcient
ROCK2−/−) mice have been generated [12,13]. Both mutant ROCK
ice were generated by knocking in a lacZ reporter gene. In the
OCK2−/− mouse, LacZ staining was observed in many locations
hroughout the embryo, including the dorsal root ganglions, heart,
iver, and umbilical blood vessels. In the placenta, strong LacZ stain-
ng was also observed in the labyrinth layer. In the ROCK1−/−
ouse, LacZ staining was also detected throughout the embryo,
ncluding the aorta, dorsal root ganglia, heart, skin, and umbilical
lood vessels. ROCK2−/− embryos were embryonically lethal due to
lacental dysfunction and intrauterine growth retardation caused
y thrombus formation in the labyrinth layer of the placenta.
OCK1−/− mice, however, die postnatally due to an abnormality of
lamentous actin accumulation, leading to impairment in umbili-
al ring closure. The ROCK1−/− mice also exhibit eyes open at birth
EOB) due to disorganization of actin ﬁlaments in the epithelial cells
f the eyelid. However, a substantial proportion of ROCK2−/− mouse
mbryos also exhibit EOB and omphalocoele, indicating that both
OCK1 and ROCK2 may  play important roles in mediating eye and
mbilical ring closure. Further studies regarding the speciﬁc roles
f ROCK1 and ROCK2 will be necessary by using haploinsufﬁcient or
onditional knockout mice. It has been reported that the haploin-
ufﬁcient ROCK1 knockout mice are viable and healthy at birth, and
xhibit decreased cardiac ﬁbrosis, but not hypertrophy, in response
o angiotensin II infusion. Decreased neointima formation in ligated
arotid artery because of less leukocyte-mediated inﬂammation in
OCK1+/− mice has been reported as well [14,15].diology 60 (2012) 1–6
Although the homology of the kinase domain between ROCK1
and ROCK2 is pretty high, ROCK1 and ROCK2 may  serve different
functions and may  have different downstream target proteins. Most
of the downstream targets of ROCKs are cellular proteins associated
with the regulation of the actin cytoskeleton. The difﬁculty with
studying the roles of ROCKs is due to the lack of speciﬁc inhibitors,
which can distinguish not only the roles of ROCK isoforms. There-
fore, a genetic approach using conditional or haploinsufﬁcient
ROCK1 and ROCK2 knockout mice offers the best opportunity to
dissect the functions of ROCK1 and ROCK2.
Y-27632 and fasudil are selective ROCKs inhibitors, which target
their ATP-dependent kinase domains, and therefore, are equipotent
in terms of inhibiting both ROCK1 and ROCK2. However, at higher
concentrations, these ROCKs inhibitors could also inhibit other
kinases such as PKA and PKC. Thus, current commercially avail-
able ROCKs inhibitors are not entirely speciﬁc for ROCKs compared
to other serine-threonine kinases in vivo, and cannot distinguish
between ROCK1 and ROCK2 [6,16].
Regulation of ROCKs
The Rho GTPases, Rho, Rac, and Cdc42, are involved in the regu-
lation of vital cellular functions such as cytoskeleton organization,
motility, proliferation, adhesion, apoptosis, and gene expression
[2]. In particular, RhoA regulates the assembly of actin stress ﬁbers
[17], while Rac and Cdc42 regulate actin polymerization and cellu-
lar protrusions [17]. As with other Rho GTPases, RhoA functions as a
molecular switch, cycling between an active GTP-bound form and
inactive GDP-bound form. The cycle between active and inactive
forms is controlled by several regulatory proteins, including gua-
nine dissociation inhibitors (GDIs), guanine nucleotide exchange
factors (GEFs), and GTPase activating proteins (GAPs) [1].  Rho GEFs
activate RhoA by catalyzing the exchange of GDP to GTP, while Rho
GAPs inactivate RhoA by dephosphorylating GTP to GDP. The GDIs
prevent the membrane translocation of RhoA from the cytosol. To
date, numerous proteins have been identiﬁed as potential Rho GEFs
and GAPs.
The carboxyl-terminal regions of ROCKs, which contain the
PH and RBD, serve as an autoregulatory inhibitor of the amino-
terminal kinase domain. The interaction of GTP-bound RhoA to
RBD of ROCKs increases ROCK activity through de-repression of the
carboxyl-terminal RBD-PH domains on the amino-terminal kinase
domain, leading to an active “open” kinase conformation. This open
conformation could also be caused by the binding of arachidonic
acid to the PH domain or cleavage of the carboxyl-terminus by
caspase-3. Such regulatory mechanism could also be found with
DMPK and MRCK activation, and is consistent with studies show-
ing that overexpression of various carboxyl-terminal constructs
of ROCKs or kinase-defective forms of full-length ROCKs, func-
tions as dominant-negative ROCK mutants. Interestingly, ROCKs
could also be activated independently of RhoA through amino-
terminal transphosphorylation caused by protein oligomerization.
Other small GTP-binding proteins such as Gem and Rad speciﬁ-
cally regulate either ROCK1- and ROCK2-mediated cell rounding
and neurite retraction [18].
Downstream targeted proteins of ROCKs
ROCKs phosphorylate various targets and mediate a broad range
of cellular responses that involve the actin cytoskeleton. ROCKs
control assembly of the actin cytoskeleton and cell contractility via
phosphorylation of various downstream target proteins including
MBS  on MLCP, MLC, ERM proteins, protein LIM kinase, and adducin.
Of interest, ROCKs can be auto-phosphorylated, suggesting that the
function of ROCKs may  be, in part, dependent on auto-regulation
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shear stress, insulin, estrogen, bradykinin, and VEGF. Interestingly,
inhibition of RhoA or ROCKs lead to the rapid activation of PI3K/Akt
and phosphorylation of eNOS [29], suggesting the potential role ofK. Noma et al. / Journal
19]. MBS  on MLCP is an important downstream target of ROCKs.
hosphorylation of MBS  on MLCP by ROCKs leads to the phos-
horylation of MLC  and subsequent contraction of VSMC. MLCP
oloenzyme is composed of three subunits: a catalytic subunit
PP1), a MBS  composed of a 58 kD head and 32 kD tail region, and
 small non-catalytic subunit, M21. ROCK2 phosphorylates MBS  at
hr697, Ser854, and Thr855 [20]. The functional signiﬁcance of MBS
hosporylation at Ser854, however, is not known. Phosphorylation
f Thr697 or Thr855 attenuates MLCP activity and in some instances,
he dissociation of MLCP from myosin. In addition, MLC is also one
f the major downstream target proteins of ROCKs. ROCK2 phos-
horylates Ser19 of MLC, the same residue that is phosphorylated
y MLC  kinase. Thus, ROCK2 may  increase cellular contractility via
ual effects on MLC  kinase and MLCP. Indeed, ROCK2 can alter
he sensitivity of VSMC contraction in response to changes in Ca2+
oncentration [3].  ROCKs also phosphorylate ERM proteins, lead-
ng to actin cytoskeletal reorganization. However, it is not known
hether phosphorylation of MBS  of MLCP or ERM proteins is spe-
iﬁc to ROCK isoforms.
OCKs function
ROCKs are central regulators of cellular apoptosis, metabolism,
rowth, and migration via control of the actin cytoskeletal assem-
ly and cell contraction. Inhibitors of ROCKs such as Y-27632 and
asudil, or overexpression of dominant-negative mutants of ROCKs,
ause loss of actin stress ﬁbers and focal adhesion complexes. This is
redominantly due to the phosphorylation and inhibition of MLCP
y ROCKs, which increase MLC  phosphorylation and cellular con-
raction by fascilitating interaction of myosin with F-actin. Thus,
OCKs regulate cell polarity and migration through cellular con-
ractions, protrusions, and focal adhesions. By affecting tight and
dherens junctions through actin cytoskeletal contractions, ROCKs
an also regulate macrophage phagocytic activity and endothelial
ell permeability.
ROCKs could regulate other cellular functions independent of
heir effects on the actin cytoskeleton. For instance, ROCKs inhibit
nsulin signaling via direct phosphorylation of insulin receptor
ubstrate-1 (IRS-1). Phosphorylation of IRS-1 uncouples the insulin
eceptor from phosphatidylinositol-3 kinase (PI3K) and potentially
lut-4 activation. ROCKs could also regulate cell size via enhancing
GF-induced CREB phosphorylation, which may  be the underlying
echanism by which ROCK inhibitors reduce cardiac hypertro-
hy [21]. However, recent studies in haploinsufﬁcient ROCK1+/−
ice indicate that ROCK1 is required for the development of car-
iac ﬁbrosis, not hypertrophy [14]. Interestingly, ROCKs may  be
nvolved in tissue differentiation from adipocytes to myocyte [22].
rosstalk between ROCKs and endothelial function
There is increasing evidence that RhoA/ROCK pathway regulates
ndothelial nitric oxide synthase (eNOS), which is well-known as a
ivotal mediator for endothelial function [23]. Indeed, inhibition
f RhoA geranylgeranylation by 3-hydroxy-3-methylgulutaryl-
oenzyme A (HMG-CoA) reductase inhibitors or statins, could
ecrease the membrane GTP-bound active RhoA and subsequent
OCK activity, leading to eNOS upregulation and activation [23].
n the meantime, Rac1 has been also reported to be essential for
tatins-mediated cardiovascular protective effects. Thereby, the
recise mechanism of statins-mediated pleiotropic effect is still
ontroversial [24]. A direct inhibition of RhoA/ROCK signaling path-
ay by ROCKs inhibitors or dominant-negative mutant of RhoA has
een also reported to increase eNOS expression [25]. Since eNOS
s well-known to be vascular protective, these studies suggest thatdiology 60 (2012) 1–6 3
RhoA/ROCK pathway may  play a signiﬁcant pathophysiological role
in various aspects of cardiovascular disease.
The vascular endothelium secretes vasoactive substances such
as NO, prostacyclin, endothelium-derived hyperpolarizing factor,
and endothelins. In particular, endothelium-derived NO plays an
important role in the regulation of vascular tone, inhibition of
platelet aggregation, suppression of smooth muscle cell prolif-
eration, and prevention of leukocyte recruitment to the vessel
wall. Increased bioavailability of NO is, in part, dependent upon
increased expression and activity of eNOS as well as decreased
inactivation of NO by reactive oxygen species (ROS), speciﬁcally
superoxide anion. Although various conditions and factors such
as laminar shear stress, oxygen tension, and TGF-1 can regulate
eNOS expression at the transcriptional level, eNOS expression can
be also regulated at the post-transcriptional level. For example,
chronic hypoxia, TNF- [26], thrombin, oxidized LDL, and cellular
proliferation are known to decrease eNOS mRNA stability. Chronic
hypoxia and cellular proliferation are known to activate RhoA and
ROCKs. In contrast, statins, which have been shown to increase
eNOS mRNA stability, inhibit RhoA geranylgeranylation and ROCK
activity. Thus, RhoA/ROCK inversely regulates eNOS expression
through alteration in eNOS mRNA stability.
Previous studies have shown that 3′-untranslated region com-
plexes (3′-UTR) of eNOS mRNA, which consists of UC-rich region
and AU-rich region, regulates the stability of eNOS mRNA by multi-
ple cytosolic proteins binding to the 3′-UTR of eNOS mRNA [27]. For
example, cytosolic proteins, which bind to the eNOS mRNA 3′-UTR
following TNF- stimulation, lead to the reduction of eNOS mRNA
half-life in human endothelial cell [26]. Since RhoA/ROCK pathway
and the actin cytoskeleton also regulate eNOS mRNA half-life [28],
it is likely that cytosolic proteins, which bind to the 3′-UTR eNOS
mRNA, are actin cytoskeletal-associated proteins. Further accu-
mulating evidence as to the mechanism to prolong eNOS mRNA
stability would be awaited with great respect.
The RhoA/ROCK pathway may  also be important in regulating
eNOS activity. The activity of eNOS is dependent on intracellular
Ca2+ concentration. There is increasing evidence that eNOS activ-
ity is also partly dependent upon eNOS interacting proteins and
post-translational modiﬁcation of eNOS. For example, eNOS activ-
ity could be regulated, in part, through association with caveolin-1,
porin, Dynamin, G protein-coupled receptors, heat shock protein
90, and various protein kinases. In addition, the regulation of eNOS
activity can also occur via eNOS phosphorylation. The phosphoryla-
tion of Ser1177 of eNOS, leads to the rapid activation of eNOS by ﬂuidFig. 1. Correlation of atherosclerosis with ROCK activity and endothelial function.
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OCKs in regulating eNOS activation in addition to eNOS expres-
ion. Although the phosphorylation of Ser1177 leads to increase
NOS activity, the phosphorylation of Thr495 is associated with a
ecrease in eNOS activity [30]. In addition, although other phospho-
ylation sites have been identiﬁed on eNOS protein such as Ser114,
er633, and other tyrosine residues, the precise functional roles of
hese phosphorylation sites remain to be determined. Interestingly,
 ROCKs inhibitor-induced vasodilation was shown to be mediated
y endothelium-derived NO in a clinical study [31]. Meanwhile, it
as been also reported that NO could inhibit RhoA/ROCK signal-
ng as well [32,33].  Consistent with previous studies, we  have also
ound that endothelial dysfunction correlates with increased ROCK
ctivity in humans [34,35]. Collectively, there is critical crosstalk
etween ROCKs and endothelial function (Fig. 1).
OCKs and cardiovascular diseases
Inhibition of RhoA/ROCK pathway may  be beneﬁcial in car-
iovascular diseases and could be a potential therapeutic target.
peciﬁcally, the RhoA/ROCK pathway has been shown to be
nvolved in diabetes mellitus [14], angiogenesis, atherosclerosis,
erebral and coronary vasospasm, cerebral ischemia, erectile dys-
unction, hypertension [36], myocardial hypertrophy, myocardial
schemia-reperfusion injury, neointima formation [37], pulmonary
ypertension [38], and vascular remodeling. In many of these stud-
es, the underlying protective mechanism of ROCKs inhibition was
ediated by the upregulation of eNOS. However, in other studies,
he protective effects of ROCKs inhibition were mediated by the
cute activation of eNOS via the PI3K/Akt pathway [25].
In a clinical study, it has been also demonstrated that ROCKs are
nvolved in patients with systemic hypertension [5],  pulmonary
ypertension [6],  vasospastic angina [39], stable effort angina [40],
troke [41], myocardial ischemia [42], and chronic heart failure [6].
hus, the development of ROCKs inhibitors could contribute the
eneﬁcial effects in patients with cardiovascular disorders.rosclerosis-related diseases.
ROCK activity as a surrogate marker on
atherosclerosis-related diseases
Usage of surrogate markers for atherosclerosis-related diseases
is quite important to prevent the cardiovascular mortality and mor-
bidity. Blood pressures, heart rate and lipid proﬁles have been
used as classical surrogate markers for a long time. Indeed, an
appropriate surrogate marker which is dependent on each stage
of atherosclerotic status should be used in order to monitor and
predict the future events accurately (Fig. 2). Among them, leuko-
cyte ROCK activity has been recently demonstrated to be quite a
useful surrogate marker for atherosclerosis-related diseases due
to the property of its physiological and pathological roles [43].
So far, leukocyte ROCK activity has been shown to be elevated in
patients with coronary artery diseases [44], metabolic syndrome
[45], coronary vasospasm [46], and atherosclerosis [47]. Especially
in patients with coronary vasospasm, not only increased leukocyte
ROCK activity can independently predict the presence of coronary
vasospasm, but also correlated with vasospasm severity [48]. Addi-
tionally, it has been also reported that treatment with anti-spastic
agents could reduce the leukocyte ROCK activity. We also demon-
strated that leukocyte ROCK activity substantially correlate with
Framingham risk score, which is a risk calculator and an index of
cumulative cardiovascular risk commonly used for assessing heart
attack or death from heart disease within 10 years, indicating that
leukocyte ROCK activity possibly predicts cardiovascular mortality
and morbidity [49].
Conclusions
Accumulating evidence is revealing that RhoA/ROCK pathway
plays an important pathophysiological role in cardiovascular dis-
eases. Indeed, inhibition of ROCKs by ROCKs inhibitors or statins
may  be beneﬁcial, in which most part of the effects may be medi-
ated through improved endothelial function. Therefore, inhibition
of ROCKs may be a novel and possible therapeutic target for
 of Car
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ardiovascular disorders. It has been well-known that endothe-
ial dysfunction is the initial step of atherosclerosis. Also, a portion
f endothelial function is regulated by ROCK activity, and a part
f ROCK activity is regulated by NO as well. Further understand-
ng of substantial crosstalk between ROCK activity and endothelial
unction would contribute the beneﬁcial effects in patients with
therosclerosis-related diseases. Especially, the development of
soform speciﬁc inhibitors would be awaited with great respect.
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